Effects of Pyrola japonica Extracts on Osteoclast Differentiation and Bone Resorption

녹제초 추출물이 파골세포 분화 및 골 흡수에 미치는 영향

  • 박정식 (가천대학교 한의과대학) ;
  • 임형호 (가천대학교 한의과대학)
  • Received : 2019.03.28
  • Accepted : 2019.04.12
  • Published : 2019.04.30


Objectives This study was performed to evaluate the effect of Pyrola japonica extract (NJ) and its principal constituent, homoarbutin (HA) on osteoclast differentiation and gene expression and bone resorption. The osteoclastogenesis and gene expression were determined in receptor activator of nuclear factor kappa B ligand (RANKL)-stimulated RAW264.7 cell. Methods In order to evaluate the effect of HA extracted from NJ on bone resorption, osteoclasts were used to be differentiated and formed by stimulating RAW264.7 cells with RANKL. Tartarate-resistant acid phosphatase (TRAP) (+) polynuclear osteoclast formation ability was evaluated, and differentiation control genes including cathepsin K, matrix metalloproteinases-9 (MMP-9), and TRAP in osteoclast differentiation were analyzed by real-time polymerase chain reaction (PCR). Immunoblotting was performed to measure the effect of mitogen-activated protein kinase (MAPK) factors on bone resorption, and the effect of osteoclasts on osteoclast differentiation was measured. Results Both NJ and high concentration of HA blocked RANKL-stimulated differentiation from RAW264.7 cell to TRAP-positive multinucleated cells. NJ reduced RANKL-induced expression of TRAP, cathepsin K. Both NJ and high concentration of HA inhibited RANKL-mediated expression of MMP-9, nuclear factor of activated T-cells, cytoplasmic 1, and cellular Jun-fos. NJ suppressed RANKL-stimulated expression of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase, tumor necrosis factor-alpha, and levels of interleukins. Both NJ and HA decreased bone resorption in osteoclast-induced bone pit formation model. Conclusions These results suggest that NJ and HA blocked bone resorption by decreasing RANKL-mediated osteoclastogenesis through down-regulation of genes for osteoclast differentiation.


  1. Thompson WR, Rubin CT, Rubin J. Mechanical regulation of signaling pathways in bone. Gene. 2012;503(2): 179-93.
  2. The Society of Korean Medicine Rehabilitation. Korean Medicine Rehabilitation. 4th ed. Paju:Koonja Publishing. 2015:133.
  3. Michou L, Brown JP. Genetics of bone diseases: Paget's disease, fibrous dysplasia, osteopetrosis, and osteogenesis imperfecta. Joint Bone Spine. 2011;78(3):252-8.
  4. Hiasa M, Abe M, Nakano A, Oda A, Amou H, Kido S, Takeuchi K, Kagawa K, Yata K, Hashimoto T, Ozaki S, Asaoka K, Tanaka E, Moriyama K, Matsumoto T. GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme(TACE). Blood. 2009;114(20):4517-26.
  5. Fujisaki K, Tanabe N, Suzuki N, Kawato T, Takeichi O, Tsuzukibashi O, Makimura M, Ito K, Maeno M. Receptor activator of NF-kappa B ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase- 9 in osteoclast precursor RAW264.7 cells. Life Sciences. 2007;80(14):1311-8.
  6. Chang EJ, Ha J, Huang H, Kim HJ, Woo JH, Lee YK, Lee ZH, Kim JH, Kim HH. The JNK-dependent CaMK pathway restrains the reversion of committed cells during osteoclast differentiation. Journal of Cell Science. 2008;121(15):2555-64.
  7. Kim DS, Kim YI. The Literatural study on the oriental cognizance and acupuncture-moxibustion therapy of osteoporosis. Journal of Haehwa Medicine. 2009;18(1):9-18.
  8. Jung BS, Shin MK. Encyclopedia of herbal medicine. 1st ed. Seoul:Yoengrim Publishing. 1990:670.
  9. Park JH, Do WI. Pharmacognostical Studies on the Nok Je Cho. Kor J Pharmacognosy. 2007;38(1):45-9.
  10. Son IK, No BK, Byun JH, Song HJ, Shin MK. Effects of herba pyrolae extract on the immune inflammatory responses and the functions of immunocytes in the mouse. Kor J Herbology. 1998;13(1):95-117.
  11. Kim JS, Shim SH, Xu YN, Kang SS, Son KH, Chang HW, Kim HP, Bae KH. Phenolic glycosides from Pyrola japonica. Chem Pharm Bull (Tokyo). 2004; 52(6):714-7.
  12. Ahn DK. Illustrated Book of Korean Medicinal Herbs. 1st ed. Seoul:Kyohak Publishing. 2008:593.
  13. Kim SY, Jeon JM, Cheon JH, Lee SH, Kong CS, Kim YY, Yu KH, Kim MH. Effects of Eisenia bicyclis extracts on the proliferation and activity of osteoblasts and osteoclasts. J Life Sci. 2014;24(3):297-303.
  14. Goode A, Layfield R. Recent advances in understanding the molecular basis of Paget disease of bone. J Clin Pathol. 2010;63(3):199-203.
  15. Liu BY, Wu PW, Bringhurst FR, Wang JT. Estrogen inhibition of PTH-stimulated osteoclast formation and attachment in vitro: involvement of both PKA and PKC. Endocrinology. 2002;143(2):627-35.
  16. Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC. Glucocorticoids and tumor necrosis factor ${\alpha}$ increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem. 2011;286(52):44326-35.
  17. Mabilleau G, Pascaretti-Grizon F, Basle MF, Chappard D. Depth and volume of resorption induced by osteoclasts generated in the presence of RANKL, TNF-alpha/ IL-1 or LIGHT. Cytokine. 2012;57(2):294-9.
  18. Ye S, Fowler TW, Pavlos NJ, Ying P, Liang K, Feng Y, Zheng M, Kurten R, Manolagas SC, Zhao H. LIS1 regulates osteoclast formation and function through its interactions with dynein/dynactin and Plekhm1. PLoS One. 2011;6(11):e27285.
  19. Henriksen K, Karsdal MA, Taylor A, Tosh D, Coxon FP. Generation of human osteoclasts from peripheral blood. Methods Mol Biol. 2012;816:159-75.
  20. Sung B, Oyajobi BO, Aggarwal BB. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling. Mol Cancer Ther. 2011;11(2): 350-9.
  21. Mukherjee A, Rotwein P. Selective signaling by Akt1 controls osteoblast differentiation and osteoblast-mediated osteoclast development. Mol Cell Biol. 2011;32(2): 490-500.
  22. Xu S, Wang Y, Lu J. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. Rheumatol Int. 2011;32(11):3397-403.
  23. Wisutsitthiwong C, Buranaruk C, Pudhom K, Palaga T. The plant limonoid 7-oxo-deacetoxygedunin inhibits RANKL-induced osteoclastogenesis by suppressing activation of the NF-${\kappa}B$ and MAPK pathways. Biochem Bioph Res Co. 2011;415(2):361-6.
  24. Dougall WC. Osteoclast-dependent and-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res. 2012;18(2):326-35.
  25. Dore RK. The RANKL pathway and denosumab. Rheum Dis Clin N Am. 2011;37(3):433-52.
  26. Matsumor T. New extension and future trends in study of RANKL-RANK. Clinical Calcium. 2011;21(8):1119-20.
  27. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6(10):e25900.